AbbVie aims for FDA filing on first hep C drug in 2014's second quarter

With Gilead's ($GILD) pioneering hepatitis C drug sofosbuvir moving closer to a likely approval and a megablockbuster market, AbbVie ($ABBV) is looming from behind with some promising results from the first of 6 Phase III studies of its breakthrough triple-threat therapy. And AbbVie is vowing today that the successful late-stage effort sets the stage for a regulatory filing in the second quarter of 2014. Report